Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Mirati Therapeutics Inc. (MRTX) Report Updated: Oct 15, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Mirati Therapeutics Inc. (MRTX)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up downgrade
service keys

Mirati Therapeutics Inc.© quotemedia

Company Profile

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. Its clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors indications, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, which is in Phase 1 clinical development for the treatment of patients with non-small cell lung cancer and solid tumors; and Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkins lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. The company has a collaboration agreement with MedImmune Limited for a trial of a combination of inhibitors for the treatment of non-small cell lung cancer; and a collaboration with Foundation Medicine, Inc. to develop lung cancer diagnostic test. Mirati Therapeutics, Inc. is headquartered in San Diego, California.